Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 15/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 13/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 13/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20734387 | 1.00 | KDM4E (0.45) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL20808834 | 1.00 | KDM4E (0.45) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL20809274 | 1.00 | KDM4E (0.45) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL20734516 | 1.00 | KDM4E (0.45) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL28513739 | 0.98 | KDM4E (0.44) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL25277658 | 0.80 | CYP2D6 (0.45) | CYP2D6CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16579395 | 0.80 | CYP2D6 (0.45) | CYP2D6CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10179987 | 0.80 | CYP2D6 (0.45) | CYP2D6CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL9977121 | 0.80 | CHRNB2 (0.36) | NOS2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL26925512 | 0.80 | CYP2D6 (0.45) | CYP2D6CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377714-B2 | Trans-isomeric heterocyclic compounds and preparation thereof | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-08-13 | — | — | US | disclosed |
| WO-2019048923-A2 | TRANS-ISOMERIC HETEROCYCLIC COMPOUNDS AND PREPARATION THEREOF | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-03-14 | — | — | WO | disclosed |
| US-20190047956-A1 | TRANS-ISOMERIC HETEROCYCLIC COMPOUNDS AND PREPARATION THEREOF | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377714-B2 | Trans-isomeric heterocyclic compounds and preparation thereof | C1S, FURIN, C5 | KDM4E 4699/4885MAPT 2716/4885KMT2A 4354/4885 |
| US-20190047956-A1 | TRANS-ISOMERIC HETEROCYCLIC COMPOUNDS AND PREPARATION THEREOF | C1S, FURIN, C5 | KDM4E 4699/4885MAPT 2716/4885KMT2A 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.